Citius Pharmaceuticals Receives Nasdaq Extension to Meet $1 Bid Price

What Happened

• Citius Pharmaceuticals, Inc. (CTXR) announced in an 8‑K filed August 21, 2026 that it received formal notice from Nasdaq on August 17, 2026 granting an extension through February 8, 2027 to cure noncompliance with the $1.00 per share minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
• If CTXR’s common stock closes at $1.00 or more for at least ten consecutive business days before February 8, 2027, Nasdaq will confirm compliance. If the company does not regain compliance by that date, Nasdaq will issue a delisting notice and CTXR may appeal to a Nasdaq hearings panel. The Extension Notice does not affect current trading; CTXR continues to trade on The Nasdaq Capital Market under the symbol “CTXR.”

Key Details

• Nasdaq extension received: August 17, 2026; extension runs through February 8, 2027.
• Compliance trigger: closing bid price ≥ $1.00 for a minimum of 10 consecutive business days (per Nasdaq Rule 5550(a)(2)).
• Current status: common stock remains listed and trading on Nasdaq (symbol CTXR) while the company evaluates options.
• If compliance is not regained by Feb 8, 2027, Nasdaq will notify the company that the stock is subject to delisting; the company may appeal.

Why It Matters

• For investors, this filing signals a continued risk of Nasdaq delisting if CTXR cannot restore its share price above $1.00 for the required period. Delisting could reduce liquidity and limit access to broader capital markets.
• The extension buys the company time to pursue measures to regain compliance, but it does not guarantee success; the company explicitly states there is no assurance it will be able to meet the Bid Price Rule even if other listing requirements are met.